084990 · KOSDAQ · ₩084990 · 헬릭스미스
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−63.7% from the high
₩2,725Today: ₩3,585 – ₩3,730₩9,960
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
Helixmith (헬릭스미스, KRX: 084990) is listed on KOSDAQ, in the Biotech & Pharma sector. Helixmith is a Korean R&D-focused biotech company founded in 1996 that develops drug candidates and offers drug development platform services such as plasmid DNA, retrovirus, and AAV based services. Its shares closed at ₩3,620 on Oct 29, 2026, down 2.95% on the day, giving it a market value of ₩167B.
Helixmith is a Korean R&D-focused biotech company founded in 1996 that develops drug candidates and offers drug development platform services such as plasmid DNA, retrovirus, and AAV based services. It also develops natural-product functional ingredients and sells health functional foods and premium cosmetics through B2B business, including its cubyN health food brand. Its main customers include Nutramax Laboratories and Dong-A Pharmaceutical, and its sales are mainly generated in Korea and abroad.
Written by AI from the company's latest annual report.
Predicted impact: Medium· Actual: +1.2% vs sector, volume 0.9× normal (5 trading days)
First commercial shipment and royalty inflows; small company, meaningful relative to its market value.
Titles in Korean until English translations are added.
Also known as: Helixmith / 헬릭스미스 / 084990 / KRX:084990
Source: KRX statistical information